EUVIMEDEUVIMED entdecken
Multizentrische Studie

Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia

Sophie Béliard iD, Samir Saheb iD, Stéphanie Litzler-Renault, Alexandre Vimont iD, René Valero iD, Éric Bruckert iD, Michel Farnier iD, Antonio Gallo iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-06 · 44 (6) · 1447-1454

DOI: 10.1161/atvbaha.123.320609 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-06. Verfasst von Sophie Béliard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, APHM, INSERM, INRAE, C2VN, Marseille, France (S.B., R.V.). Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Cholesterol, LDL, Homozygote, Angiopoietin-Like Protein 3. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal antibody, more than halves low-density lipoprotein cholesterol in short-term studies. This study evaluated whether the evinacumab response was durable in the long term and improved cardiovascular outcome. METHODS: The OLE ELIPSE HoFH (Open-Label Extension to Evinacumab Lipid Studies in Patients With HoFH) study included newly diagnosed patients and those completing the ELIPSE HoFH trial, on stable lipid-lowering therapy including lipoprotein apheresis but not lomitapide. All patients received evinacumab (15 mg/kg intravenously) every 4 weeks, with no change in concomitant lipid-lowering treatment during the first 6 months. The primary efficacy end points were the mean absolute and percentage changes in low-density lipoprotein cholesterol from baseline to 6 months. A key secondary end point was cardiovascular event–free survival, which was compared with a control HoFH cohort not treated with evinacumab or lomitapide and matched for age, sex, and lipoprotein apheresis, derived from French Registry of Familial hypercholesterolemia. RESULTS: Twelve patients, 5 women and 7 men (12–57 years), were enrolled in 3 centers in France. At 6 months, the mean low-density lipoprotein cholesterol reduction with evinacumab was 3.7 mmol/L or 56% (from 6.5 mmol/L at baseline to 2.8 mmol/L; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IICholesterol, LDLHomozygoteAngiopoietin-Like Protein 3Anticholesteremic AgentsHumansMaleFemaleAdultMiddle AgedBlood Component RemovalBiomarkersAntibodies, MonoclonalTime FactorsProgression-Free SurvivalYoung AdultTreatment OutcomeCardiovascular DiseasesAdolescent

Stichwörter der Autor:innen

cardiovascular diseaseshomozygous familial hypercholesterolemiamyocardial infarctionrisk factorssurvival

Substanzen

evinacumabCholesterol, LDLAngiopoietin-Like Protein 3Anticholesteremic AgentsBiomarkersAntibodies, MonoclonalANGPTL3 protein, human

Autor:innen und Institutionen

  • Aix Marseille University, APHM, INSERM, INRAE, C2VN, Marseille, France (S.B., R.V.).
  • APHM, Department of Nutrition, Metabolic Diseases, Endocrinology, La Conception Hospital, Marseille, France (S.B., R.V.).
  • Sorbonne Université, Lipidology and Cardiovascular Prevention Unit, Hémobiothérapie Unit, APHP, Hôpital Pitié-Salpètriêre, Paris (S.S.).
  • Université de Bourgogne, Pediatric Intensive Care and Monitoring Unit, CHU Dijon, France (S.L.-R.).
  • Department of Public Health Expertise, Paris, France (A.V.).
  • Centre ELLA Santé, Paris, France (E.B.).

ORCID-Profile: Sophie Béliard, Samir Saheb, Alexandre Vimont, René Valero, Éric Bruckert, Michel Farnier, Antonio Gallo

Zitieren

APA

Béliard, S., Saheb, S., Litzler-Renault, S., Vimont, A., Valero, R., Bruckert, É., Farnier, M., & Gallo, A. (2024). Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(6), 1447-1454. https://doi.org/10.1161/atvbaha.123.320609

Vancouver

Béliard S, Saheb S, Litzler-Renault S, Vimont A, Valero R, Bruckert É, et al. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(6):1447-1454. doi:10.1161/atvbaha.123.320609

BibTeX
@article{Bliard2024,
  author = {Béliard, Sophie and Saheb, Samir and Litzler-Renault, Stéphanie and Vimont, Alexandre and Valero, René and Bruckert, Éric and Farnier, Michel and Gallo, Antonio},
  title = {Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  volume = {44},
  number = {6},
  pages = {1447--1454},
  doi = {10.1161/atvbaha.123.320609}
}
Kostenlos starten →